Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Visiongain Reports | The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023

The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market.

Visiongain forecasts that OTC pharmaceutical sales will almost double from 2007 levels by 2023. In the period 2008-2023, the worldwide OTC market will undergo a period of dynamic change. Increasingly aging populations and rising incidence of lifestyle diseases, as well as the need to reduce healthcare costs, will open up new therapeutic areas for OTC switching. Likewise, sales of existing OTC products will rise. At the same time, changes in retail patterns and new ways of advertising will open up access to OTC drugs to a public better educated and more interested in self-medication than at any previous time. Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Consequently, the commercial prospects are very good for companies well placed to serve those growing needs. In these difficult times for the global pharmaceutical industry, OTC sales will become increasingly important, visiongain concludes.

In particular, this report concentrates on the following essential aspects of the global OTC industry:

• Major therapeutic areas treated by OTC products

• Key industrial players in the OTC market

• Financial forecasts covering the period 2008-2023, including leading brands, countries and therapeutic areas

• Geographical breakdown of the market

• Sales of the highest-selling OTC brands and other relevant information

• Coverage of prescription-only to OTC switching in the pharma industry

Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the OTC industry from 2008-2023, including sales by therapeutic area and country

• To discover predicted revenues, growth rates and other key metrics for OTC pharmaceuticals from 2008-2023, including those of leading brands

• To discover possible future OTC switching candidates

• To determine the forces that influence the OTC market:

• Drivers and restraints on market

• Competition

• Strengths, weaknesses, opportunities and threats

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

- PRICING -

- Single use licence $2995.00

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00

July 2008
Table of Contents

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions